Oncology Clinics Frustrated With Manufacturer Engagement Tactics

Article

Oncology Clinics Frustrated With Manufacturer Engagement Tactics

June 11, 2024
Authors
Topics

Welcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.

Frustrated man surrounded by technology, papers, people.

The oncology toolbox is growing rapidly, with novel treatments or expanded uses being approved almost monthly. Understandably, manufacturers seek to ensure that oncologists are informed of the details for new and existing treatments, and community oncologists generally find product updates to be highly useful. However, an increasingly crowded market is forcing companies to compete for the limited time physicians and practices can allocate for these meetings.

Our 2024 Community Oncology Annual Trend survey examined practices’ points of view toward manufacturers’ digital engagement to identify frustrations arising from current approaches (Figure). HMP Market Access Insight’s (MAI’s) research suggests that manufacturers who engage with providers on their terms are more likely to avoid these causes of frustration.

Figure showing data described in article.

Figure. Prevalence and Causes of Community Oncology Practices’ Frustrations. (A) Perceived frustrations and inefficiencies with digital manufacturer communications (N = 124 practices). (B) Top three oncology clinic frustrations with manufacturer engagement tactics (N = 113 practices).
Source: HMP Market Access Insights 2024 Community Oncology Annual Trend report. 

Key findings include:

  • Overall frustration: 91% of surveyed practices have declared some type of frustration with current manufacturer engagement tactics.
  • Inefficient communication: 55% of practices believe they are receiving excessive email communication, and 52% have experienced uncoordinated meeting requests from different representatives at the same manufacturer. This demonstrates a need for more streamlined and coordinated communication strategies.
  • “Meet clinics where they are”: 54% of practices report that they receive communication at inconvenient times. Manufacturers may increase communication effectiveness by aligning their engagements with practices’ daily schedule.

We look forward to sharing additional insights later this month when we release our full 2024 Community Oncology Annual Trend report!

Meanwhile, be sure to check out some of our newly available reports and keep an eye out for our other upcoming offerings:

If your organization is interested in learning more about our offerings, please contact Sara Stewart.

The Latest

Frustrated man surrounded by technology, papers, people.
Article
Oncology Clinics Frustrated With Manufacturer Engagement Tactics

Welcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.

Ashutosh Sheth
Doctor looking at papers
Article
When Do Payer Pathways Matter?

While provider-initiated oncology clinical pathways are regaining momentum, payer pathways struggle to find a foothold in this space. Still, they can exert impact under certain conditions.

Cindy Chen
Stock image of person holding pills behind a graph
Article
IDNs’ Numerous Strategies and Tools to Manage High-Cost Drugs

Welcome to the May 2024 edition of our Monthly Insight Series. This month we’re exploring the new tools IDNs have deployed to monitor high-cost drugs. This is a preview of findings from our 2024 IDN Oncology Trend Survey, coming at the end of May.

Emma Bijesse